BiotechTube

BGS649 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypogonadotropic Hypogonadism

Conditions

Hypogonadotropic Hypogonadism

Trial Timeline

May 12, 2016 → May 19, 2018

NCT ID
NCT02730169

About BGS649 + Placebo

BGS649 + Placebo is a phase 2 stage product being developed by Mereo BioPharma for Hypogonadotropic Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT02730169. Target conditions include Hypogonadotropic Hypogonadism.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02730169Phase 2Completed

Competing Products

3 competing products in Hypogonadotropic Hypogonadism

See all competitors
ProductCompanyStageHype Score
Investigational new drug company code: BGS649 + PlaceboNovartisPhase 2
52
Corifollitropin alfa + hCGOrganonPhase 3
72
BGS649Mereo BioPharmaPhase 2
44

Other Products from Mereo BioPharma

Alvelestat (MPH966)Phase 2
44
BCT197 + PlaceboPhase 2
44
Pemetrexed + Carboplatin + demcizumabPhase 2
44
Nivolumab + EtigilimabPhase 2
44
Placebo Oral Tablet + Alvelestat oral tablet - dose 1 + Alvelestat oral tablet - dose 2Phase 2
44